Gate Neurosciences

We’re on a mission to address the needs of millions of patients suffering from mental health disorders by re-thinking what’s possible in CNS drug development

[Gate Neurosciences @GateNeuro]

Check out our spotlight piece in Drug Discovery World's summer issue! Co-founder Dr. Anantha Shekhar shares perspectives on the challenges and opportunities for neuroplastogen therapies in #mentalhealth

[Drug Discovery World @DDWJournal]

The Summer issue of Drug Discovery World (DDW) is out now!

Read the digital version here:
https://t.co/HPXFpYDgLv

#DrugDiscovery

[BioWorld @BioWorld]

.@GateNeuro and @biosignals illuminate depression biomarkers with EEG https://t.co/FCOhML5E8B #biotech #pharma

[Gate Neurosciences @GateNeuro]

Happy to announce our collab with @biosignals to advance #precisionmedicine in neuropsychiatry! We will be including their Dreem 3S headband in our upcoming zelquistinel Phase 2 trial in MDD to explore novel EEG biomarker endpoints

[Beacon Biosignals @biosignals]

Excited to partner with @GateNeuro for a Phase 2 trial on zelquistinel to treat major depressive disorder! 🚀 Leveraging FDA-cleared Dreem 3S headband & our AI Analytics, we're bringing precision to psychiatry with novel EEG biomarkers and sleep endpoints!
https://t.co/Ai0IUmYWRn

[Beacon Biosignals @biosignals]

Excited to partner with @GateNeuro for a Phase 2 trial on zelquistinel to treat major depressive disorder! 🚀 Leveraging FDA-cleared Dreem 3S headband & our AI Analytics, we're bringing precision to psychiatry with novel EEG biomarkers and sleep endpoints!
https://t.co/Ai0IUmYWRn

[Inside Precision Medicine @Inside_PM]

Gate Neurosciences Collaborates with Beacon Biosignals to Leverage EEG Biomarkers in Major Depressive Disorder. Learn more: https://t.co/aEnAsJ01wO

[Gate Neurosciences @GateNeuro]

Our lead program, zelquistinel, was included in a recent review paper from @UTHealthHouston on GABA-glutamate targeted drugs:
https://t.co/MpBMh5C8kq

"Future treatment models need to consider nuances of glutamate signaling with regard to timing & duration of action"...we agree!

[Gate Neurosciences @GateNeuro]

Nice @TheAtlantic piece on how psychedelics hallucinogenic effects may not drive #mentalhealth outcomes - its the impact on neuroplasticity. Our novel drug candidates can safely enhance plasticity & strengthen neural connections to treat disease from #MDD to #alzheimers & #autism

[The Atlantic @TheAtlantic]

A new generation of psychedelics could offer mental-health benefits to a huge number of people.

The secret: no trips, highs, or hallucinations, @raf_ideas writes: https://t.co/AereWtegsi

[Gate Neurosciences @GateNeuro]

We're excited to share the latest clinical trial results for our rapid-acting IV antidepressant, apimostinel. These new qEEG #biomarker data reflect NMDAR activation and enhanced synaptic function, to help guide future clinical trials. Link: https://t.co/1yLjbpZqsf

#mentalhealth

[Gate Neurosciences @GateNeuro]

Great to see coverage in @WIRED on the link between #neuroplasticity and #depression.

Current antidepressants take weeks to work. We are developing a new class of drugs targeting the #glutamate system to rapidly enhance neuroplasticity within hours to days.

#mentalhealth

[WIRED @WIRED]

A clinical trial reveals the first evidence of how the brain restructures physically in the first month on SSRIs—and the link between neuroplasticity and depression. https://t.co/R29ZqQuhc1

[Drug Discovery & Development @DrugDiscoverDev]

In this article, Gate Neurosciences details their role on taking on depression with event-driven #pharmacology.

They also discuss he challenges & promise of NMDA receptor #modulation, the role of EEG #biomarkers in #DrugDevelopment & much more: https://t.co/6DE0twGWHU

[Gate Neurosciences @GateNeuro]

As part of our commitment to #mentalhealth innovation, we recently expanded our research facilities in Evanston! This renewed effort includes advancing translational EEG biomarkers supporting our '-stinel' programs that enhance synaptic function.

https://t.co/R3sbRbZ0TX

[Michael G McCully @Mike_McCully]

I will be in Boston next week at the Cowen Healthcare Conference Mar 6-8. Looking forward to seeing everyone. We are making great progress at Gate Neuro and have news forthcoming about our expanded R&D and results from our clinical biomarker study. #neuroscience #mentalheath

[Michael G McCully @Mike_McCully]

The underlying mechanism of ketamine in depression requires downstream NMDAR-activation. New publication from Todd Gould (https://t.co/rcwa65NX8b)
https://t.co/BTYwOndSTj

[Gate Neurosciences @GateNeuro]

Gate Neuro was recently featured in @PsychTimes ! Co-founder Dr. Anantha Shekhar discusses our ongoing biomarker study with apimostinel, a rapid-acting and safe NMDAR modulator in development for acute depressive disorders. #mentalhealth #precisionmedicine
https://t.co/tdqOaBdrCR

[Gate Neurosciences @GateNeuro]

This week we announced dosing the first patient cohort in a translational EEG biomarker study of apimostinel. Press release: https://t.co/LowSZu4RxF

[Gate Neurosciences @GateNeuro]

Gate is committed to #mentalhealth innovation. This morning we announced a publication on the novel NMDA mechanism underlying rapid, durable & safe activity with our lead oral program in Phase 2: https://t.co/VSWAa71TeF

Link to paper in IJNP: https://t.co/PYYVVC3hFc

#biotech

[Gate Neurosciences @GateNeuro]

We are excited to officially emerge from stealth! A big thanks to our team, investors, and @abbvie and @LillyPad for their partnership in assembling our next-generation CNS portfolio. Learn more about us here: https://t.co/d86FFAg5X0

#neuroscience #mentalhealth #biotech